Lipocine (LPCN) Stock Highlights

4.87 | +4.06%

2024-12-21 07:30:03

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The companys product TLANDO, is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.

Statistics

Range Today

4.7 5

Volume Today 64.3K

Range 1 Year

2.44 11.79

Volume 1 Year 11.26M

Range 3 Year

2.31 32.13

Volume 3 Year 31.4M

Range 10 Year

2.31 326.91

Volume 10 Year 116.49M

Highlights

Market Capitalization 25.46M (micro)

Floating Shares 5.19M

Current Price 4.87

Price To Earnings -4

Price To Revenue 2.1

Price To Book 1.24

Earnings Per Share -1.38

Payout Ratio 0%

Performance

Latest +4.06%

1 Month +2.96%

3 Months +2.74%

6 Months -35.07%

1 Year +70.88%

3 Years -72.45%

5 Years -15.3%

10 Years -94.48%

Benchmarks

Market Capitalization

326 / 368

Gross Profits

134 / 278

Total Revenue

300 / 300

Total Rank

331 / 368

Free Cashflow

86 / 352

Performance 5 years

134 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.